Knowledge graph · Drug
Necitumumab
monoclonal antibody
- Identifier
- CI-DRUG-00000727
- Entity page
- /drug/necitumumab ↗
- Edges
- 37
- Neighbours
- 9 cancers1 genes10 trials1 approvals
- Drawn
- 21 of 21 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Necitumumab approved for …APPROVED_FORderived2 of 2 | ||||||||
| → approved for | Lung Non-Small Cell Carcinomasubtype EMA (EU) · withdrawn · 2016-02-15 · Portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced… | — | withdrawn | Lung Non-Small Cell Carcinoma | 1 | Regulatory | ema | graph → |
| → approved for | ||||||||